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1. Introduction 
The stomach plays a pivotal role in the digestion of foods that we eat. With the exception of 
rare cases, this organ can resist to a large variety of noxious factors, including hydrochloric 
acid, refluxed bile salts and alcohol, with a wide range of temperatures and osmolality. This 
high resistance to injuries depends on a number of physiological responses elicited by the 
mucosal lining against potentially harmful luminal agents, as well as to the ability of rapidly 
repairing the mucosal damage when it does occur (Laine et al., 2008). Nevertheless, when 
these protective mechanisms are overwhelmed by injurious factors, a gastric mucosal lesion 
may develop. Major detrimental effects on gastric mucosa are exerted by non-steroidal anti-
inflammatory drugs (NSAIDs). These drugs are able not only to exert gastric injuring effects, 
but also to delay the healing of ulcer lesions through a variety of local and systemic 
mechanisms (Musumba et al., 2009).  
Since the discovery that prostaglandin biosynthesis could be inhibited by NSAIDs through 
the blockade of cyclooxygenase enzymes, there has been a great interest in the contribution 
of prostaglandins to the mechanisms of gastric mucosal defense. Thus, it has been 
appreciated that these lipidic mediators are able to modulate virtually every factor involved 
in mucosal protection, and the importance of this contribution is made evident by the 
increased susceptibility of the stomach to injury following the intake of NSAIDs. Indeed, 
chronic treatments with these drugs can be associated with the development of ulcers in the 
stomach, and research over the past two decades has helped to identify some of the key 
events, triggered by cyclooxygenase blockade, which take part to ulcer formation and/or 
impairment of ulcer healing. Since many years, it has been recognized that NSAIDs can 
interfere with gastric mucosal physiology also through injuring mechanisms unrelated to 
the inhibition of prostaglandin biosynthesis, such as oxidative stress and changes in 
epithelial cell proliferation/apoptosis balance.  
Following the discovery of two isoforms of cyclooxygenase (COX-1 and COX-2), and based 
on the assumption that COX-2 was an inducible enzyme responsible for inflammation, but 
devoid of gastroprotective functions (Vane et al., 1998), selective COX-2 inhibitors (coxibs, 
including celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib and lumiracoxib) were 
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clinically developed as novel anti-inflammatory/analgesic drugs characterized by reduced 
gastric toxicity (Dubois et al., 2004). These advances have then fostered intensive preclinical 
and clinical research supporting the view that coxibs may confer advantages over 
conventional non-selective NSAIDs in terms of gastrointestinal risk reduction. Nevertheless, 
there are still a number of unresolved issues in this field, and the criteria for an appropriate 
use of coxibs in patients with various degrees of gastrointestinal risk, including ongoing 
gastric ulcerations, remain matter of discussion. 
Another relevant topic, regarding the integrity of gastric mucosa, is represented by the use 
of proton pump inhibitors (PPIs). These drugs have been proven not only to prevent 
NSAID-induced upper gastrointestinal injury, but also to promote the healing process once 
the damage has occurred, even in the presence of a continued NSAID administration. The 
beneficial effects of PPIs can be largely ascribed to their ability to maintain a sustained 
inhibition of gastric acid secretion. However, there is also evidence to suggest that 
pharmacodynamic properties unrelated to acid inhibition may contribute to the therapeutic 
actions of these drugs (Blandizzi et al., 2008).  
Recent research has highlighted the fact that, beside prostaglandins, gastric mucosal 
protective functions can be accomplished by other mediators, with particular regard for the 
gaseous mediators nitric oxide (NO) and hydrogen sulfide (H2S). Moreover, anti-
inflammatory drugs endowed with dual cyclooxygenase/5-lypooxygenase inhibitory 
effects, such as licofelone, could represent novel therapeutic strategies helping to drive the 
development of safer anti-inflammatory drugs and effective therapies to accelerate and 
improve the quality of ulcer healing (Blandizzi et al., 2009). 
This chapter is focused on the available evidence on the molecular mechanisms underlying 
the pathophysiology of gastric injury development and healing, as well as on novel 
therapeutic options for prevention and treatment of gastric ulcers. 
2. Mechanisms of gastric mucosal defense 
The mechanisms of gastric mucosal defense include several local and neurohormonal 
protective factors, which allow the mucosa to resist against frequent exposures to damaging 
factors (Laine et al., 2008). In the following sections, a detailed description of the mucosal 
defense mechanisms is provided.  
2.1 Local mechanisms of gastric mucosal defense 
2.1.1 Mucus-bicarbonate-phospholipid barrier 
The first line of gastric mucosal defense is represented by the mucus-bicarbonate-
phospholipid barrier (Lichtenberger, 1999). The surface of gastric mucosa is covered by a 
layer formed by mucus gel, bicarbonate anions and surfactant phospholipids. This unstirred 
layer is capable of retaining the bicarbonate ions secreted by surface epithelial cells and 
maintaining a microenvironment with a pH near to 7 at the mucus-mucosa interface. The 
mucus layer is also able to prevent the penetration of pepsin, thus avoiding the proteolytic 
digestion of epithelium (Allen and Flemstrom, 2005). In addition, the luminal surface of 
mucus gel is covered by a film of surfactant phospholipids which confers hydrophobic 
properties to the mucus layer (Lichtenberger, 1999).  
The mucus gel is secreted by surface epithelial cells and is formed by a large amount of 
water (about 95%) and various kinds of mucin glycoproteins (i.e., MUC2, MUC5AC, 
MUC5B and MUC6), the production of which may vary in different regions of the gastric 
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mucosa (Allen and Flemstrom, 2005; Ho et al., 2004). Gel-forming mucin units polymerize 
into large mucin multimers, which are essential for gel formation. The mucus gel is secreted 
along with low-molecular weight trefoil factor (CRF) family (TFF) peptides, which play a 
relevant role in the formation of the mucus layer (Newton et al., 2000). For example, TFF2 is 
known to increase the viscosity of gastric mucin and stabilize the gel network (Thim et al., 
2002). The secretion of gastric mucus is regulated also by various gastrointestinal hormones, 
including gastrin and secretin, as well as prostaglandins and acetylcholine (Allen and 
Flemstrom, 2005).  
The secretion of bicarbonate into the mucus gel layer is essential to maintain a pH gradient 
at the epithelial surface, which represents a first line of defense against gastric acid (Allen 
and Flemstrom, 2005). Bicarbonate secretion from the apical membrane of surface epithelial 
cells is mediated by a Cl-/HCO3- anion exchanger, and it is stimulated by various factors, 
including prostaglandins (via EP1 receptors), luminal acid, corticotrophin-releasing factor, 
melatonin, uroguanylin and orexin A (Allen and Flemstrom, 2005; Montrose et al., 2006). 
The mucus-bicarbonate barrier is the only system which segregates the epithelium from the 
gastric lumen. Therefore, when this protective barrier breaks down during pathological 
events or upon detrimental actions by injuring agents, a second line of protective 
mechanisms comes into play. They include intracellular acid neutralization, rapid epithelial 
repair, and maintenance of mucosal blood flow.  
2.1.2 Epithelial cells 
The continuous layer of surface epithelial cells represents the next line of mucosal defense. 
This epithelial tissue is responsible for the production of mucus, bicarbonate and other 
components of the gastric mucosal barrier. These cells are hydrophobic in nature, being able 
to repel acid- and water-soluble injuring agents, owing to the presence of phospholipids on 
their surface (Lichtenberger, 1999). Surface epithelial cells are also closely interconnected by 
tight junctions, forming a continuous barrier, which prevents back diffusion of acid and 
pepsin (Allen and Flemstrom, 2005). Another relevant protective factor, available in the 
epithelial cells, is represented by heat shock proteins, which are activated in response to 
stress, including temperature increments, oxidative stress and cytotoxic agents (Tanaka et 
al., 2007). These proteins can prevent protein denaturation and protect cells against injury. 
Cathelicidin and beta-defensin are cationic peptides which play a relevant role in the innate 
defensive system at the mucosal surface, preventing bacterial colonization (Yang et al., 
2006). In addition, TFFs secreted by epithelial cells regulate the re-epithelization process and 
exert mucosal protective actions (Taupin and Podolsky, 2003). 
2.1.3 Mucosal cell renewal 
The integrity of gastric epithelium is maintained by a continuous process of cell renewal 
ensured by mucosal progenitor cells. These cells are subjected to a continuous, well 
coordinated and controlled proliferation, which ensures the replacement of damaged or aged 
cells on the epithelial surface. The process of complete epithelial renewal takes about 3-7 days, 
while the overall glandular cell replacement requires months. However, the restitution of 
surface epithelium after damage occurs very quickly (i.e., few minutes) and results by 
migration of preserved cells located in the neck area of gastric glands (Laine et al., 2008).  
The process of cell turnover is regulated by growth factors. In particular, a marked 
expression of epidermal growth factor receptor (EGF-R) has been detected in gastric 
progenitor cells. Such a receptor can be activated by mitogenic growth factors, such as 
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transforming growth factor- (TGF-) and insulin-like growth factor-1 (IGF-1) (Nguyen et 
al., 2007). In addition, PGE2 and gastrin are able to transactivate the EGF-R and promote the 
activation of mitogen-activated protein kinase (MAPK) pathway, with consequent 
stimulation of cell proliferation (Pai et al., 2002). Notably, the presence of EGF has not been 
detected in the normal mucosa, although it is contained in the gastric juice, as a product of 
salivary and esophageal glands, and can stimulate mucosal cell proliferation in case of 
injury (Milani and Calabrò, 2001). In addition, mucosal progenitor cells do express survivin, 
an antiapoptotic factor, which inhibits apoptotic cell death (Chiou et al., 2005). 
2.1.4 Mucosal blood flow 
Mucosal blood flow is essential to deliver oxygen and nutrients and to remove toxic 
metabolites from gastric mucosa. Arteries embedded into the muscularis mucosae branch 
into capillaries, which then enter the lamina propria and travel toward the proximity of 
glandular epithelial cells. Endothelial cells, lining these microvessels, produce NO and 
prostacyclin (PGI2), which act as potent vasodilators, thus protecting the gastric mucosa 
against damage and counteracting the detrimental effects of various vasoconstrictors, 
including leukotriene C4, thromboxane A2, and endothelin. In addition, NO and PGI2 
maintain the viability of endothelial cells and inhibit platelet and leukocyte adhesion to the 
microvasculature, thus preventing the occurrence of microischaemic phenomena (Laine et 
al., 2008).  
When the gastric mucosa is exposed to irritants or acid back-diffusion, a massive and rapid 
increase in mucosal blood flow occurs. This process allows removal and dilution of back-
diffusing acid or noxious agents. The increase in blood flow is regarded as a pivotal 
mechanism for preventing gastric mucosal cell injury, and its decrease results in the 
development of tissue necrosis. The increase in mucosal blood flow is mediated by NO 
release, and there is experimental evidence demonstrating that NO protects the gastric 
mucosa against injury induced by ethanol or endothelin 1, while the inhibition of NO 
synthase enhances mucosal injury (Holzer, 2006). It has been also observed that another 
endogenous compound, H2S, can exert protective actions against gastric mucosal injury. In 
particular, this compound has been shown to reduce the expression of tumor necrosis factor 
 (TNF-), to decrease leukocyte adhesion to vascular endothelium, and to prevent NSAID-
induced gastric mucosal damage (Fiorucci et al., 2006). 
2.1.5 Sensory innervation 
The vasculature of gastric mucosa and submucosa is innervated by extrinsic primary 
afferent sensory neurons, which are arranged in a plexus at the base of the mucosal layer 
(Holzer, 2007).  The nerve fibers stemming from this plexus run along with capillary vessels 
and reach the basal membrane of surface epithelial cells. These nerves can detect luminal 
acidity or back-diffusing acid through acid-sensing channels. The activation of such sensory 
nerves modulates the contractile tone of submucosal arterioles, thus regulating the mucosal 
blood flow. In particular, the stimulation of sensory nerves  leads to the release of calcitonin 
gene-related peptide (CGRP) and substance P from nerve terminals surrounding large 
submucosal vessels (Holzer, 2007). CGRP then contributes to the maintenance of mucosal 
integrity through the vasodilation of submucosal vessels mediated by NO release. Sensory 
innervation plays a prominent role in the protection of gastric mucosa from injury, as 
demonstrated by studies where the ablation of sensory transmission (i.e., with capsaicin) 
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impaired the vasodilatatory response and increased the sensitivity of gastric mucosa to 
injuring agents (Holzer, 2007). 
2.1.6 Prostaglandins 
The gastric mucosa represents a source of continuous prostaglandin production, such as 
PGE2 and PGI2, which are regarded as crucial factors for the maintenance of mucosal 
integrity and protection against injuring factors (Halter et al., 2001; Brzozowski et al., 2005a). 
It has been demonstrated that prostaglandins have the potential to stimulate almost all the 
mucosal defense mechanisms. In particular, they reduce acid output, stimulate mucus, 
bicarbonate and phospholipid production, increase mucosal blood flow, and accelerate 
epithelial restitution and mucosal healing (Brzozowski et al., 2005a). Prostaglandins are also 
known to inhibit mast cell activation as well as leukocyte and platelet adhesion to the 
vascular endothelium (Halter et al., 2001; Brzozowski et al., 2005a). The beneficial actions 
exerted by PGE2 have been shown to be mediated by activation of specific EP receptor 
subtypes. In particular, the activation of EP1 receptors mediates the most important 
protective effects of prostaglandins, through an increase in bicarbonate secretion and 
mucosal blood flow in the damaged mucosa and a decrease in gastric motility (Takeuchi et 
al., 2002). Other EP receptor subtypes are also involved in the protective actions of PGE2. For 
example, EP3 receptors inhibit the gastric acid secretion, while EP4 receptors stimulate the 
secretion of mucus (Kato et al., 2005).  
2.2 Neurohormonal mechanisms 
Gastric mucosal defense is supported by mechanisms activated, at least in part, by the 
central nervous system and hormonal factors (Laine et al., 2008). Experimental studies have 
demonstrated that central vagal activation stimulates mucus secretion and increases 
intracellular pH in the surface epithelial cells of in the stomach. In addition, while the CRF 
pathway is involved in endocrine responses to stress (Chatzaki et al., 2006). In addition, 
peripheral CRF contributes significantly to the regulation of gastric defense mechanisms, in 
particular, the CRF2 receptor is known to mediate antiapoptotic effects in gastric epithelial 
cells as well as to inhibit gastric emptying and motility (Chatzaki et al., 2006). 
Other hormone mediators, including gastrin-17, cholecystokinin, thyrotropin-releasing 
hormone, bombesin, EGF, peptide YY and neurokinin A, play significant roles in the 
regulation of gastric protective mechanisms, which can be blunted by afferent nerve 
ablation, CGRP receptor blockade, and inhibition of NO synthase (Peskar, 2001; Moszik et 
al., 2001). Ghrelin, a hormone peptide produced by gastric A-like cells in rodents and P/D1 
cells in humans, is involved in the regulation of growth hormone secretion and appetite 
stimulation (Brzozowski et al., 2005b). Moreover, it is also able to exert significant protective 
effects at gastric level, including the enhancement of mucosal blood flow via stimulation of 
NO and CGRP release from sensory afferent nerves (Brzozowski et al., 2005b).  
Glucocorticoids have been shown to support the mechanisms of protection at gastric level. 
These hormones are involved in the response to stress, and represent potent 
gastroprotective factors against injury (Filaretova et al., 1998). Consistently with this 
contention, glucocorticoid antagonists enhanced the severity of stress-induced erosions, 
further supporting a protective role of these hormones during stress (Filaretova et al., 2001). 
The mechanisms through which glucocorticoids exert their protective effects include the 
maintenance of glucose homeostasis, the increase in mucosal blood flow and mucus 
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secretion, and the attenuation of both enhanced gastric motility and microvascular 
permeability (Filaretova et al., 2007). 
3. Mechanisms of gastric mucosal damage 
Gastric mucosal injury may occur as a consequence of various conditions, including alcohol 
intake, refluxed bile salts, stress, aging and Helicobacter pylori infection, although the most 
important agents known to impair the mechanisms of gastric mucosal defense are 
represented by NSAIDs. For this reason, in the following sections a detailed description of 
NSAID-related mechanisms of gastric injury is provided. 
3.1 Effects of NSAIDs on gastric mucosa 
The pathophysiology of gastric injury associated with NSAID administration depends 
partly on cyclooxygenase inhibition and partly on cyclooxygenase-independent 
mechanisms, which result mainly from local direct actions (Scarpignato and Hunt, 2010). 
Cyclooxygenase blockade has been shown to increase the susceptibility of gastric mucosa to 
NSAID-induced injury by suppression of a number of prostaglandin-mediated protective 
functions. For instance, prostaglandins reduce the activation of neutrophils and the local 
release of reactive oxygen species (ROS). The production of prostacyclin by the endothelium 
of mucosal microcirculation is also highly relevant in ensuring a tonic inhibition of 
neutrophil adhesion. Therefore, NSAIDs can shift the mucosal balance toward the 
recruitment and endothelial adhesion of circulating neutrophils through the inhibition of 
prostaglandin biosynthesis (Whittle, 2002). Once adhered, neutrophils clog the 
microvasculature causing a local decrease in mucosal blood flow and a marked release of 
tissue damaging factors, including proteolytic enzymes and leukotrienes, which enhance the 
vascular tone, exacerbate tissue ischaemia, stimulate the production of ROS, and promote 
the destruction of intestinal matrix, leading to a severe degree of focal tissue necrosis, 
particularly in the presence of a low luminal pH (Whittle, 2002; Jimenez et al., 2004).  
As anticipated above, cyclooxygenase-dependent inhibition of bicarbonate secretion 
contributes also to the gastric mucosal injury elicited by NSAIDs. Indeed, the secretion of 
bicarbonate ions in the mucus gel layer generates a pH gradient on the mucosal surface, 
thus providing a first line defense against luminal acid (Allen and Flemstrom, 2005). A 
number of studies have demonstrated the expression of bicarbonate/chloride ion 
exchangers in the apical membranes of gastric surface epithelial cells, and shown that 
cyclooxygenase-derived prostaglandins stimulate bicarbonate secretion via activation of EP1 
receptors (Takeuchi et al., 1997; Rossmann et al., 1999). 
Most NSAIDs are weakly acidic in nature and this property accounts for their local 
cyclooxygenase-independent injuring actions on the gastric mucosa. In the presence of 
gastric acidity, the undissociated lipophilic form of acidic NSAIDs can impair the 
hydrophobic surface barrier of the stomach. This transformation of the gastric mucosal 
surface from a non-wettable to a wettable state appears to be linked with the ability of acidic 
NSAIDs to destabilize the extracellular lining of zwitterionic phospholipids, particularly 
phosphatidylcholine, which are present within and on surface of the mucus gel layer 
(Lichtenberger et al., 2007). Previous studies have demonstrated that such an effect 
contributes significantly to NSAID-induced gastric injury in experimental models, and that 
it can persist for prolonged periods after discontinuation of NSAID administration 
(Lichtenberger, 2001). There is also consistent evidence that the protonophore actions of 
Pathophysiology of Gastric Ulcer Development  
and Healing: Molecular Mechanisms and Novel Therapeutic Options 
 
119 
aspirin and other acidic NSAIDs take a significant part in the topical damage to gastric 
mucosa. In particular, upon exposure to the acidic environment of gastric lumen, the 
undissociated lipid-soluble form of aspirin is able to penetrate cell membranes and 
accumulate into epithelial cells, where the inner pH is at a physiological level of 7.4. At this 
pH value, aspirin dissociates and remains segregated within cells. This accumulation 
enhances the inhibition of prostaglandin biosynthesis, and it brings also into play other 
properties of aspirin, such as the uncoupling of mitochondrial oxidative phosphorylation. 
The consequences of such mitochondrial dysfunction are a decrease in ATP production and 
an increase in AMP and ADP levels, which are then responsible for increments of 
intracellular calcium concentration. These changes are followed by mitochondrial injury, 
increased generation of ROS and alterations in the Na+/K+ balance, which lead to 
weakening of the mucosal barrier and cellular necrosis (Wallace, 2001; Bjarnson et al., 2007).  
 
 
Fig. 1. Pathophysiology of gastric injury induced by non-selective NSAIDs. These anti-
inflammatory drugs exert their detrimental effects on the gastric mucosa through two key 
mechanisms: simultaneous inhibition of COX-1 and COX-2, and direct topic cytotoxic 
effects. The topic injuring actions depend on the acidic chemical structure of NSAIDs. 
Coxibs do not harm the gastric mucosa owing to their ability to selectively inhibit COX-2, 
while not affecting the protective functions of COX-1. ROS: reactive oxygen species. 
An additional mechanism, involved in the injurious effects of NSAIDs on gastrointestinal 
mucosa, is related to the detrimental actions of these drugs on the integrity of epithelial tight 
junctions, which are known to segregate the apical from basolateral cell surface domains, in 
order to establish cell polarity and provide a barrier function against the back diffusion of 
acid and other solutes through the paracellular space (Schneeberger and Lynch, 2004). It has 
been suggested that cyclooxygenase inhibition may be implicated in NSAID-induced 
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alterations of intercellular epithelial permeability (Joh et al., 2003). However, recent evidence 
indicates that aspirin can elicit gastric epithelial barrier dysfunction through down-
regulation of claudin-7, a member of the claudin protein family, which play important roles 
in the formation of tight junctions (Oshima et al., 2008). 
Coxibs do not alter the integrity of normal gastric mucosa in preclinical models, and their 
clinical development was based on the assumption that COX-2 is not expressed in the 
gastric mucosa (Laine et al., 2008). However, this initial hypothesis has not been supported 
by subsequent observations, demonstrating the constitutive presence of both COX-1 and 
COX-2 in human and rodent gastric mucosa (Zimmermann et al., 1998). In addition, studies 
on COX-1-knockout mice have provided no evidence of spontaneous gastric injury and 
demonstrated the ability of NSAIDs to damage the gastric mucosa via COX-2-dependent 
mechanisms (Langenbach et al., 1995). Wallace et al. (2000) investigated further the 
functional roles of COX isoforms in the gastric mucosa, showing that COX-1-dependent 
prostaglandins are involved in the maintenance of mucus/bicarbonate secretion and blood 
flow, while COX-2 protects the mucosa from leucocyte endothelial adhesion and supports 
epithelial renewal. In addition, these Authors observed that selective COX-1 or COX-2 
inhibitors did not damage the stomach when tested alone, while NSAIDs or the combined 
administration of COX-1 plus COX-2 selective inhibitors resulted in gastric erosions 
(Wallace et al., 2000). A schematic diagram illustrating the mechanisms of gastric mucosal 
injury exerted by cyclooxygenase inhibitors is provided in Figure 1. Overall, it is currently 
acknowledged that NSAIDs can impair gastric protection via a concomitant blockade of 
COX-1 and COX-2, while coxibs lack damaging actions on gastric mucosa by preserving 
COX-1-dependent prostaglandin production (Wallace, 2006). 
4. Mechanisms of gastric ulcer healing 
Gastric ulcer results from mucosal tissue necrosis triggered primarily by ischemia, with 
cessation of nutrient delivery and ROS formation. Tissue necrosis and subsequent release of 
arachidonic acid metabolites from injured cells, including leukotrienes B, attract leukocytes 
and macrophages, which then phagocitize the necrotic tissue and release pro-inflammatory 
cytokines, which in turn activate local fibroblasts, endothelial cells and epithelial cells to 
attempt a tissue restoration (Cotran et al., 1999; Tarnawski, 2005). Morphologically, gastric 
ulcer consists of two components: the margin, sorrounded by adjacent non-necrotic mucosa, 
and the base, consisting of granulation tissue, which is a connective tissue rich in 
macrophages, fibroblasts and proliferating microvessels (Cotran et al., 1999). Ulcer healing is 
a complex process, in which the tissue repairs itself after injury, attempting a restitution 
towards integrity. It has been proposed that such a process can be distinguished in 
sequential, partly overlapping, phases: haemostasis, inflammation, proliferation and 
remodeling (Stadelmann et al., 1998). According to Schmassmann (1998),  the phases and 
time course of ulcer healing can be described as follows: ulcer development phase (within 3 
days from injury), characterized by tissue necrosis, inflammatory infiltration, formation of 
ulcer margin (de-differentiation) and development of granulation tissue; healing phase 
(after 3-10 days from injury), which includes an early healing (rapid migration of epithelial 
cells and contraction of ulcer base) followed by a late healing (angiogenesis in ulcer bed, 
remodeling of granulation tissue and complete re-epithelialization of ulcer crater); 
reconstruction phase (day 20-40 after ulceration) consisting of the reconstruction of glands, 
muscularis mucosae and muscularis propria; maturation phase (40-150 days after 
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ulceration), characterized by maturation and differentiation of specialized cells 
(Schmassmann, 1998). 
In general, following the ulcerative injury, a set of complex biochemical events takes place to 
provide support for cellular migration from ulcer margin and attachment to the ulcer base, 
with subsequent cellular proliferation and restoration of the epithelial layer. Ulcer healing is 
initiated by formation of the ‘healing zone’, consisting of dilated glands, whose cells 
undergo de-differentiation, express epidermal growth factor receptor (EGF-R) and starts to 
actively proliferate. At this stage, inflammatory infiltration occurs closely to the necrotic 
tissue and ulcer crater. In response to growth factors, the ulcer margin is formed, cells 
adjacent to the margin de-differentiate, and granulation tissue develops at the ulcer base. 
During healing, the granulation tissue undergoes continuous remodeling, contraction and 
changes in cellular composition, whereby the inflammatory cells, appeared in the early 
phase of healing, are replaced by fibroblasts and microvessels in the late healing phase 
(Cotran et al., 1999). Wong et al. (2000) analyzed the sequential expression of various genes 
during ulcer healing and were able to distinguish the following arrays: genes involved in early 
response (EGF-R, c-fos, c-jun, egr-1, sp-1, trefoil factor-2/spasmolytic peptide [TFF-2/SP]), 
which are all activated shortly after ulcer formation (i.e., within 30 minutes-2 hours); 
intermediate response genes (EGF, basic fibroblast growth factor [bFGF], platelet derived 
growth factor [PDGF] and vascular endothelial growth factor [VEGF]), which become 
activated within 6 hours-2 days; late response genes (hepatocyte growth factor [HGF], 
intestinal trefoil factor [ITF], c-met/hepatocyte growth factor receptor [HGF-R]), which are 
activated within 14 days (Wong et al., 2000). The subsequent proliferation step is initiated 
within 3 days from ulceration, and  it is essential for the healing process, since it supplies the 
epithelial cells needed for re-epithelialization  mucosal surface and gland reconstruction of 
(Cotran et al., 1999). There is evidence that mucosal ulceration leads to the development of a 
novel cell lineage designated as ulcer associated-cell lineage, which stems from the base of 
surviving crypts (Cotran et al., 1999). These cells, which express EGF-R and initiate the 
synthesis of EGF, HGF, trefoil peptides and other growth factors, promote epithelial tube 
formation, migration and invasion of granulation tissue, and ultimately drive gland 
reconstruction within the ulcer scar (Tarnawski, 2005). Time-sequence analysis has shown 
that trefoil peptides are expressed much earlier than EGF following the induction of tissue 
ulceration. Furthermore, receptor analysis, using radioligand binding assays and 
immunohistochemistry, has shown a rapid increase in EGF-R expression and a rapid 
decrease in somatostatin receptor density in the ulcer margin (Reubi et al., 1994). 
The major stimuli for cell migration and ulcer re-epithelialization are mediated by growth 
factors which are produced by platelets, injured tissue and macrophages. Current evidence 
suggests also that the epithelium of ulcerated  mucosa can be regenerated by bone marrow-
derived adult stem cells, since biopsy specimens of gastric mucosa, obtained from female 
patients receiving bone marrow transplants from male donors, were found to contain cells 
equipped with chromosome Y (Okamoto et al., 2002). The migration of epithelial cells from 
the ulcer margin, to restore the continuity of epithelial lining, is essential for ulcer healing, 
and it is subjected to a fine regulation, since it generates a barrier protecting the granulation 
tissue from any mechanical and chemical  damage. Notably, cell migration requires complex 
cytoskeletal rearrangements. In particular, it has been appreciated that cytoplasmic 
microfilaments, consisting of G-actin, polymerize into F-actin and the latter, together with 
myosin II, provides contractile bundles through which cell motility can take place (Chai et 
al., 2004). A schematic diagram showing the main factors involved in gastric ulcer healing is 
provided in Figure 2.  
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Fig. 2. Main mechanisms involved in gastric ulcer healing. EGF: epidermal growth factor; 
PDGF: platelet-derived growth factor; TGF-β: transforming growth factor- β. 
4.1 Early primary response genes: protooncogenes 
Ulcer healing depends on a long-term array of responses, which requires de novo mRNA 
and protein synthesis as well as cell replication. Changes in gene regulation, in response to 
wounding or ulceration, result in an increase in cell proliferation to replace lost cells. To 
accomplish this task, the damaged tissue induces early primary response genes, belonging 
to the family of protooncogenes, which code for sequence-specific DNA-binding nuclear 
proteins, having the potential of directly influencing the expression of specific genes at the 
transcriptional level. Although a low basal expression of the nuclear protooncogenes c-fos, c-
jun and c-myc is usually observed in most cells, their expression can be rapidly and 
transiently up-regulated following tissue wounding (Wang and Johnson, 1994). In the rat 
stress ulcer model, it has been demonstrated that exposure to stress resulted in a rapid 
increase in c-fos and c-myc mRNA levels, up to 3-4-fold the basal value. The change in the 
expression of these protooncogenes was found to precede an increased rate of DNA 
synthesis (Wang e Johnson, 1994). In another study, based on in situ ibridization, Ito et al. 
(1990) examined the changes in protooncogenes expression during gastric regeneration after 
stress injury. In this setting, cells expressing c-myc mRNA were identified as mucous neck, 
parietal, chief and enterochromaffin-like cells, and the distribution of cells in S-phase 
coincided with that of protooncogene expressing cells (Ito et al., 1990). The exact signal 
transduction pathways, leading to protooncogene up-regulation following tissue injury, are 
still unclear, but they  are thought to result from modulation of gene transcription by the 
polyamines, spermine, spermidine and putrescine. These low-molecular-weight organic 
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cations are ubiquitous in eukariotic cells and able to bind negatively charged 
macromolecules, such as DNA, RNA and proteins, thus influencing the chromatin structure 
and sequence-specific DNA-protein interactions, with consequent changes in the regulation 
of initiation, elongation and termination of gene transcription (Li et al., 2001). 
4.2 Angiogenesis and angiogenic growth factors 
Following gastric ulcerative insults, all mucosal components, including microvessels, 
undergo destruction within the necrotic area. The healing of such deep mucosal lesions 
requires the reconstruction of surface epithelium and glandular epithelial structures, the 
restoration of lamina propria and the reconstruction of mucosal microvascular network, 
which is essential for delivery of oxygen and nutrients to the healing site (Tarnawski, 2005). 
The latter goal is achieved through angiogenesis, a finely regulated process, in which 
microvascular endothelial cells migrate from preserved microvessels at the wound edge, 
proliferate and attempt to re-establish a microvascular network through de novo vessel 
formation (Folkman and D’Amore, 1996). Angiogenesis occurs via a series of sequential 
steps, which include: degradadation of capillary basement membranes by activation of 
matrix metalloproteinases (MMPs); endothelial cell migration into the perivascular space 
and proliferation; formation of microvascular tubes followed by anastomoses; establishment 
of lamina propria and basement membranes and, ultimately, formation of a novel capillary 
network (Folkman and D’Amore, 1996). The growth of granulation tissue and generation of 
new microvessels through angiogenesis is stimulated by bFGF, VEGF, PDGF, angiopoietins, 
other growth factors and cytokines, including IL-1 and TNF- (Risau, 1997). Gastric mucosal 
angiogenesis is strongly stimulated by prostacyclin and human recombinant bFGF. 
Furthermore, the induction of mucosal injury triggers the activation of bFGF and its 
receptors, and enhances bFGF protein expression in the mucosa-bordering necrosis 
(Tarnawski, 2005). 
VEGF is a pivotal regulator of angiogenesis. It binds at least two specific receptors, VEGF-R1 
or flt-1 and VEGF-R2 or flk/KDR, which are expressed mainly on endothelial cells and 
initiate the phosphorylation of cytosolic proteins involved in signal transduction promoting 
endothelial cell proliferation, migration and microvascular formation (Ferrara, 2004). VEGF 
production is stimulated by PDGF, TGF-, cytokines, NO and prostaglandin E2. Hypoxia is 
one of the best characterized  stimuli for the induction of VEGF expression, acting via a 
hypoxia-inducible factor (HIF)-1 binding site located on the VEGF gene promoter (Ferrara, 
2004). Jones et al. (1999) demonstrated a 4-6 fold increase in VEGF mRNA and protein in the 
mucosa-bordering necrosis after 24 hours from the induction of ulcer by intragastric ethanol 
instillation. In this study, the quantitative assessment of angiogenesis demonstrated that 
almost 10% of microvessels in the mucosa-bordering necrosis displayed endothelial 
sprouting, reflecting the ongoing angiogenesis. Moreover, treatment with anti-VEGF 
neutralizing antibody reduced the angiogenic response and delayed ulcer healing (Jones et 
al., 1999). The activation of MAPK (Erk1 and Erk2) signal transduction pathway is crucial 
for VEGF-induced stimulation of angiogenesis in ulcer healing, and NSAIDs have been 
found to interfere with the angiogenic process in part by inihibiting the MAPK/Erk 
pathway (Jones et al., 1999). In normal gastric microvascular cells it has been demonstrated 
that prostaglandins can induce VEGF mRNA through transactivation of JNK by Erk2 (Pai et 
al., 2001). Moreover, this stimulant effect of prostaglandins is likely to be amplified via a 
positive feedback mechanism, since VEGF, once induced, activates COX-2 expression via an 
autocrine and paracrine action (Tamura et al., 2002). 
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4.3 Platelets 
It is becoming increasingly appreciated that the platelet has the potential of performing a 
large array of functions, in addition to its role in haemostasis. Tissue repair is initiated with 
the aggregation of platelets, formation of fibrin clot and release of growth factors from 
platelets, injured cells and extracellular matrix. Platelets represent one of the largest source 
of growth factors in the body, and it is through the release of these growth factors that, at 
least in part, platelets are capable of markedly influencing the processes of tissue healing. 
Several potent angiogenic stimulators are stored in platelets, including VEGF, platelet 
derived endothelial growth factor (PDEGF), EGF and PDGF (Perini et al., 2005). These 
factors account for the ability of platelets to stimulate endothelial cell proliferation and 
capillary-like formation. Factors that influence the platelet content of pro- versus 
antiangiogenic factors, or their release from platelets, have the potential to markedly affect 
angiogenesis and ulcer healing. For example, treatment of rats for 1 week with ticlopidine, 
an antiplatelet drug acting as adenosine diphosphate receptor antagonist, resulted in a 
marked increase in platelets and serum levels of endostatin, without affecting platelet VEGF  
levels. Moreover, this treatment resulted in a marked delay in gastric ulcer healing (Ma et 
al., 2001). Notably, among a number of receptors, that are important in regulating platelet 
adhesion, aggregation and secretion, platelet membranes have been found to express 
proteinase-activated receptors (PARs), which are G protein–coupled receptors, activated by 
proteinase cleavage at a specific site in their extracellular NH2-terminus. Four PARs have 
been cloned to date. The activation of PAR1 by thrombin stimulates the release of VEGF, 
while inhibiting the release of endostatin. By contrast, the activation of PAR4 mediates 
opposite effects on VEGF release (Ma et al., 2005). The balance in platelet and serum levels 
of pro- and antiangiogenic factors may influence the healing processes of gastric ulcer and 
raises the possibility that a selective modulation of PARs could be a viable pharmacological 
strategy for modulating ulcer healing. 
4.4 Heat shock proteins 
In response to environmental or physical stress, such as heat or ethanol, eukaryotic cells 
induce the synthesis of intracellular proteins designated as heat shock proteins (HSPs) or 
stress proteins (Tsukimi and Okabe, 2001). These proteins function as molecular chaperones, 
which participate in the folding and assembly of nascent proteins, the refolding of partial 
damaged functional proteins, and the delivery of precursor proteins to mitochondria 
(Hightower, 1991). HSPs are classified into four major families according to their biological 
activities and apparent molecular weights: HSP90, HSP70, HSP60, which are constitutively 
expressed, and small HSPs, including HSP27 and HSP10, which are inducible by various 
conditions, including oxidative stress (Hightower, 1991). Tsukimi and Okabe (2001) found 
that the level of HSP70 in normal mucosa was quite low, while it was significantly higher in 
the ulcer base at the time of ulcer development. HSP70 is expressed in proliferating cells 
during re-epithelialization (Soncin and Calderwood, 1996), and thus it is likely to be 
involved in the regeneration of ulcerated mucosa. The induction of HSP70 in the ulcer base 
might either contribute to the de novo synthesis of proteins or regulate the activity of key 
enzymes involved in ulcer healing through a molecular chaperone activity. Of note, 
Ethridge et al. (1998) reported that the overexpression of COX-2 by transfected cDNA 
inhibited the expression of HSP70 and the activation of heat shock factor-1 (HSF-1) in 
response to heat shock in rat intestinal epithelial cells. Such inhibition was antagonized by 
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the COX-2 inhibitor NS-398. Accordingly, Ethridge et al. (1998) proposed that 
prostaglandins derived from COX-2 might be associated with HSP70 induced by heat shock, 
suggesting an inverse relationship between COX-2 expression and HSP70 induction. HSP47 
is a 47 kDa stress protein that specifically binds collagen (Nagata et al., 1988). Collagen 
biosynthesis represents an essential step for granulation tissue formation. In this regard, 
HSP47 was found to be expressed in the ulcer base at the time of ulcer development, and its 
expression decreased with the progress of ulcer healing. Based on these results, it has been 
suggested that HSP47 might be involved in ulcer healing by playing a role in collagen 
biosynthesis (Tsukimi and Okabe, 2001). 
4.5 Annexin-1 
Annexin-1 is a 37-kDa member of the annexin family of proteins, which bind and activate 
‘formyl-peptide’ receptors (FPR), known to mediate immune and anti-inflammatory 
responses. These receptors are expressed on the surface on a variety of cells, including 
subepithelial myofibroblasts, smooth muscle cells, leukocytes, mast cells and T cells (Chiang 
et al., 2006). Annexin-1 can also exert its anti-inflammatory actions after proteolitic removal 
of its NH2 terminus (Martin et al., 2008). The expression of annexin-1, designated also as 
lipocortin,  can be induced by glucocorticoids and it has been shown to contribute to their 
anti-inflammatory effects (Hannon et al., 2003). In mice, annexin-1 is expressed in the 
healthy gastric mucosa, and it is markedly up-regulated following ulcer induction by acetic-
acid. In this setting, treatment of mice with an annexin-1 mimetic peptide improved gastric 
ulcer healing. Furthermore, although annexin-1 deficient mice did not exhibit any difference 
from wild-type mice in terms of susceptibility to indomethacin-induced gastric damage, the 
healing of such lesions was impaired in annexin-1-deficient mice (Martin et al., 2008). These 
data are consistent with the hypothesis that annexin-1 contributes to ulcer repair through 
mechanisms depending on its anti-inflammatory actions. Consistently with this view, 
Martin et al. (2008) observed an increased expression of the 33-kDa cleavage product of 
annexin-1 in concomitance with the up-regulation of annexin-1 in the gastric ulcer of mice. 
The expression of this cleavage product was not observed in healthy stomachs, and 
therefore it is likely that annexin-1 cleavage, probably due to elevated protease levels, 
occurred as a consequence of factors induced during the inflammatory or repair process to 
generate peptide retaining anti-inflammatory properties (Martin et al., 2008). 
4.6 Extracellular matrix and tissue remodeling 
The replacement of granulation tissue with a connective tissue scar, as well as the 
reconstruction of mucosal architecture, involves tissue remodeling and changes in the 
composition of extracellular matrix (ECM). ECM consists of fibrous structural proteins, such 
as collagens and elastins, adhesive glycoproteins, including fibronectin and laminin, and an 
amorphous gel composed by proteoglycan and hyaluronan. ECM provides the supporting 
structure for epithelial, endothelial and smooth muscle cells and it is an essential component 
of connective tissue (Cotran et al., 1999). In the acetic acid-induced gastric ulcer model, 
Shahin et al. (2001) demonstrated a marked increase in procollagen I 3 days after ulcer 
induction. Procollagen gene expression remained elevated up to day 15, while returning to 
the initial levels on day 30. The highest procollagen transcript levels were found in the intact 
submucosa surrounding the ulcer margins, followed by the muscularis propria and serosa, 
with the lamina propria displaying the lowest transcript levels (Shahin et al., 1997). Beside 
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collagens, other important components of ECM are spatially and temporally regulated 
during ulcer healing. MMPs include collagenases, which cleave the fibrillar collagens. These 
enzymes are produced by several cell types, such as fibroblast, macrophages, neutrophils, 
endothelial cells and some epithelial cells, and their secretion is induced by growth factors, 
cytokines or steroids (Cotran et al., 1999). Activated MMPs are rapidly inhibited by specific 
tissue inhibitors, designated as tissue inhibitors of metalloproteinase (TIMP), to prevent 
uncontrolled actions by proteinases (Cotran et al., 1999). It has been reported that MMP-2 
RNA expression can be detected as early as 24 hours after ulcer induction, a time point that 
coincides with the clearance of necrotic tissue (Shahin et al., 2001). Its further enhancement 
at the ulcer margin, after 48 hours, parallels the increment of ulcer diameter observed after 
the sloughing of necrotic tissue. TIMP-1 expression has been found to be enhanced at 72 
hours, suggesting that MMP-2 may promote the ulceration process through local 
degradation of matrix and tissue proteolysis (Shahin et al., 2001). 
5. Effects of NSAIDs and coxibs on gastric ulcer healing 
The  pharmacological modulation of cellular and molecular targets involved in the healing 
process can alter ulcer repair. Cell renewal in the ulcer margin and angiogenesis in the ulcer 
base have been found to be significantly impaired during NSAID treatment, with significant 
delay in ulcer healing (Levi et al., 1990). In the acetic acid-induced ulcer rat model, Sanchez-
Fidalgo et al., (2004)  found that the ulcerated area was characterized by increased bFGF 
expression and microvessel density in the granulation tissue at the ulcer base, in 
concomitance with increments of both apoptotic cell death and expression of proliferation 
cellular nuclear antigen (PCNA), a marker of cell proliferation. In this setting, both rofecoxib 
(a selective COX-2 inhibitor) and ibuprofen (a non selective NSAID) delayed ulcer healing, 
but only rofecoxib was found to reduce all the above mentioned parameters. More recently, 
indomethacin was tested for its effects on ulcer healing, PCNA and activated caspase-3 
expression in acetic acid-induced gastric ulcers. In this study, indomethacin was found to 
delay ulcer healing, and to up-regulate caspase-3 but not PCNA in ulcerated tissues, 
suggesting that apoptotic cell death represents a relevant mechanism whereby NSAIDs can 
impair ulcer repair (Colucci et al., 2009).  
Prostaglandins are known to stimulate angiogenesis in vivo and in vitro (Mehrabi et al., 
2001; Cheng et al., 1998). Therefore, it is likely that drugs acting as cyclooxygenase blockers, 
such as NSAIDs, can interfere with angiogenesis in the setting of gastric ulcer healing. Tsujii 
et al. (1998) showed that aspirin, a non selective NSAID, and NS398, a selective COX-2 
inhibitor, blocked angiogenesis in cultured human umbilical vein endothelial cells. Some 
clinical and experimental data support the view that both non-selective NSAIDs and COX-2 
selective inhibitors can delay gastric ulcer healing, partly by inhibiting angiogenesis in the 
granulation tissue at the ulcer base (Tarnawski and Jones, 2003). In particular, indomethacin 
significantly reduced (by >37%) the number of microvessels in the ulcer granulation tissue, 
and the selective COX-2 inhibitors L-745,337, celecoxib and NS398 were found to exert 
similar effects (Tarnawski and Jones, 2003). The mechanisms by which NSAIDs inhibit 
angiogenesis appear to include a local change in angiogenic growth factor expression, 
alterations in key regulators of VEGF, increased endothelial cell apoptosis, inhibition of 
endothelial cell migration and recruitment of inflammatory cells and platelets (Tarnawski 
and Jones, 2003). In rat primary aortic endothelial cells, indomethacin and NS398 markedly 
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inhibited the tube formation and Erk2 nuclear translocation. Incubation with prostaglandins 
partly prevented the NS398-induced effects, but not those exerted by indomethacin, 
suggesting that both COX-1 and COX-2 are important for the regulation of ulcer 
angiogenesis, and that the inhibitory action of NSAIDs on angiogenesis depends on both 
prostaglandin-dependent and prostaglandin-independent mechanisms (Tarnawski and 
Jones, 2003). Pai et al. (2001) have proposed that NSAIDs can arrest endothelial cell 
proliferation by suppressing cell cycle proteins, since indomethacin was found to 
significantly inhibit bFGF-stimulated endothelial cell proliferation by reducing cyclin D1 
and increasing p21 protein expression. Furthermore, in a study carried on microvascular 
endothelial cells, indomethacin and NS398 were found to be able to inhibit VEGF-induced 
early growth response factor (Egr) 1 gene activation, which is a transcription factor activated 
by hypoxia in angiogenesis (Szabo et al., 2001). Ma et al. (2002) examined the effects of 
cyclooxygenase inhibitors on the healing of gastric ulcer in rats, angiogenesis in granulation 
tissue, and serum levels of VEGF and endostatin. In this study, both celecoxib, a selective 
COX-2 inhibitor, and flurbiprofen, a non-selective NSAID, significantly impaired 
angiogenesis, delayed ulcer healing and increased serum endostatin levels (Ma et al., 2002). 
There is also evidence that NSAIDs can interfere with ulcer healing by both acid-dependent 
and acid-independent mechanisms (Schmassmann, 1998). In this respect, an experimental 
study has shown that: the thick granulation tissue below the ulcer crater was transformed 
into a thinner mature scar within 2 weeks from ulceration; in the presence of NSAIDs, the 
thickness of granulation tissue progressively increased, indicating an inhibition of its 
maturation process, and the ulcer healing was delayed; such detrimental effect of NSAIDs 
on the remodeling of granulation tissue could be reversed by omeprazole, suggesting the 
involvement of acid-dependent mechanisms (Schmassmann et al., 1995). 
As anticipated above, preclinical studies have shown that the impairing actions of NSAIDs 
on ulcer healing can be shared by COX-2 selective inhibitors, suggesting a role for COX-2 in 
the process of ulcer repair. However, there is also evidence supporting the view that factors 
other than COX-2 could be important in the detrimental effects of NSAIDs and selective 
COX-2 inhibitors on ulcer healing (Blandizzi et al., 2009). First of all, data regarding COX-2 
expression in gastric ulcer tissue are conflicting. Furthermore, Schmassmann et al. (2006)  
observed that treatment with selective COX-1 inhibitors did not delay ulcer healing in COX-
1 knockout mice and wild type animals. However, in the same study, the combination of 
selective COX-1 and COX-2 inhibitors impaired ulcer healing to a higher extent than 
selective COX-2 inhibitors alone, suggesting that COX-1 could also contribute to ulcer 
healing process under a condition of COX-2 inhibition.  It has been suggested also that the 
detrimental action of aspirin in combination with celecoxib on ulcer healing could result 
from the ability of aspirin to alter surface phospholipids, without significant involvement of 
the cyclooxygenase pathways (Lichtenberg et al., 2007).  More recently, we have obtained 
preliminary evidence that the ulcer healing impairing effects exerted by treatment with 
indomethacin (COX-1/COX-2 inhibitor) or DFU (selective COX-2 inhibitor) could depend 
on the ability of these drugs to induce the expression of NSAID activated gene-1 (NAG-1), 
which is known to promote apoptosis (Colucci et al., 2008). 
6. Effects of PPIs on gastric mucosal protection and ulcer healing 
Several preclinical and clinical lines of evidence have demonstrated that PPIs are highly 
effective in promoting the healing of gastric damage induced by NSAIDs, even in the 
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presence of a continued NSAID administration, through the activation of both acid-
dependent and -independent mechanisms (Blandizzi et al., 2008).  
PPIs are substituted benzimidazole derivatives (Figure 3) endowed with potent inhibitory 
effects on gastric acid secretion. 
 
OMEPRAZOLE LANSOPRAZOLE PANTOPRAZOLE
ESOMEPRAZOLE RABEPRAZOLE
 
Fig. 3. Chemical structure of proton pump inhibitors (PPIs) 
These drugs act primarily through the blockade of the enzyme H+/K+-adenosine 
triphosphatase (H+/K+-ATPase, the so-called “proton pump”), which is activated during the 
final step of acid secretion by the parietal cells of the stomach. PPIs are weak basic 
compounds, with acid dissociation constant (pKa) values ranging from 3.9 to 5.0. For this 
reason, they accumulate massively in the highly-acidic secretory canalicula of parietal cells, 
where they are rapidly converted into their active cyclic sulfenamide form. This highly 
reactive sulfenamide derivative binds sulfidryl groups of H+/K+-ATPase, leading to 
permanent enzyme inhibition and subsequent potent reduction of acid secretion (Boparai et 
al., 2008). Some studies have suggested that the beneficial effects of PPIs on ulcer healing 
could be ascribed to a marked inhibition of acid secretion, which can lead to a consistent 
increase in plasma gastrin levels, a peptide actively involved in the regulation of mucosal 
cell proliferation (Koh and Chen, 2000). However, the evidence supporting the involvement 
of gastrin in the healing action of PPIs is conflicting and there is no general consensus on the 
significance of this mechanism. Ito et al. (1994) initially showed that omeprazole was 
effective in increasing the healing rate of acetic acid-induced gastric ulcers in rats, and that 
this effect was related to a marked increase in serum gastrin levels. In a subsequent study, 
Schmassmann and Reubi (2000) observed that both omeprazole, inducing 
hypergastrinaemia, and exogenous gastrin-17 enhanced cell proliferation in the ulcer 
margin, with an acceleration of the healing process. Since these ameliorative effects were 
reversed by treatment with a gastrin receptor antagonist, the authors suggested that 
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omeprazole promoted ulcer healing through an increase in cell proliferation secondary to 
hypergastrinaemia. However, Okabe and Amagase (2005) provided evidence that a 
somatostatin analogue significantly decreased the omeprazole-induced hypergastrinaemia 
in rats with gastric ulcers, while not affecting the ability of this PPI to stimulate ulcer 
healing. In addition, the healing effect of omeprazole was not modified by gastrin receptor 
antagonists, thus suggesting that gastrin, released in response to omeprazole, played a 
marginal role in the mechanisms underlying the ulcer healing action of this PPI. 
Besides the marked inhibition of gastric acid secretion, increasing evidence indicates that the 
beneficial effects of PPIs against NSAID-induced gastric injury could depend on acid-
independent mechanisms. For instance, it has been shown that these drugs are able to 
counteract tissue oxidative damage in a direct or indirect manner (Lapenna et al., 1996; 
Natale et al., 2004). In particular, several in vitro experiments demonstrated a direct 
antioxidant activity of PPIs, showing that pantoprazole (Fornai et al., 2005) and lansoprazole 
(Blandizzi et al., 2005) concentration-dependently reduced copper-induced oxidation of 
human native low density lipoproteins (LDLs), while omeprazole behaved as a scavenger of 
hypochlorous acid (an oxidant compound generated by phagocytes) (Lapenna et al., 1996). 
Other studies have shown that pantoprazole is able to scavenge hydroxyl radicals, produced 
during a Fenton reaction, through the interaction with the hydroxyl radical generating 
system (Simon et al., 2006). Interestingly, in vitro experiments demonstrated that 
omeprazole and lansoprazole protected DNA from oxidative damage generated by 
hydroxyl radicals (Biswas et al., 2003). When considering the indirect antioxidant 
mechanisms, it has been observed that PPIs can significantly counteract the oxidative stress 
arising from polymorphonuclear cell activation. In this regard, omeprazole was shown to 
reduce neutrophil functions (Wandall, 1992), including adhesion processes to endothelial 
cells (Suzuki et al., 1999), phagocytosis and acidification of phagolysosomes (Agastya et al., 
2000), and the production of ROS (Zedtwitz-Liebenstein et al., 2002). In addition, 
lansoprazole inhibited the release of free oxygen radicals from neutrophils activated by 
Helicobacter pylori (Suzuki et al., 1995). Recently, Martins de Oliveira et al. (2007) showed that 
omeprazole and pantoprazole inhibited H+K+-ATPase in neutrophils, resulting in cationic 
flow disturbances and subsequent suppression of migration and intracellular events, such as 
calcium influx and p38 MAPK activation. On the same line, Pastoris et al. (2008) 
demonstrated that, in addition to inhibiting acid secretion, the effects exerted by 
esomeprazole against indomethacin-induced gastric damage can be partly ascribed to a 
reduction in gastric oxidative injury. 
It is also worthy to mention a novel mechanism contributing to the acid-independent 
beneficial effects of PPIs, which are able to induce and subsequently increase the catalytic 
activity of heme oxygenase-1 (HO-1) (Becker et al., 2006). The antioxidant, anti-
inflammatory, anti-apoptotic, and vasodilatory properties of HO-1 pathway products, such 
as bilirubin and carbon monoxide, can counteract the main mechanisms of gastric damage. 
In particular, HO-1 plays a key role in the physiological tissue defense as well as in the 
modulation of ulcer healing process (Becker et al., 2006). 
Mucosal depletion of sulphydryl radicals has been found to take part to the pathogenesis of 
gastric lesions evoked by different NSAIDs (Villegas et al., 2002), and reduced glutathione 
(GSH) concentrations have been detected in mucosal biopsies from patients with NSAID-
induced gastric bleeding (Savoye et al., 2001). Consistently with these findings, gastric 
injury evoked by indomethacin in rats was shown to be associated with a significant 
decrease in mucosal GSH concentration, and treatment with esomeprazole protected the 
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gastric mucosa against indometacin-induced damage by restoring mucosal GSH levels 
(Pastoris et al., 2008). 
The involvement of cyclooxygenase/prostaglandin pathways in the ulcer healing 
mechanisms activated by PPIs has been investigated with conflicting evidence. Some reports 
suggested that gastric mucosal levels of PGE2 were unaffected by treatment with PPIs 
(Natale et al., 2004; Fornai et al., 2011). By contrast, Tsuji et al. (2002) reported that 
lansoprazole increased gastric COX-2 expression and PGE2 production after repeated 
administrations in rats, and suggested that such increments resulted from a lansoprazole-
induced increase in gastrin secretion. 
Some studies have investigated the modulating effects of PPIs on several molecular markers 
of cell proliferation and apoptosis, in order to better characterize the mechanisms 
contributing to their ulcer healing actions. In this respect, Colucci et al. (2009) observed that 
the ability of esomeprazole to counteract the detrimental action of indomethacin on ulcer 
repair was ascribable to an enhancement of NF-kB activation and to a decrease in caspase-3-
dependent apoptosis. Interestingly, these effects were found to likely depend on acid-
independent mechanisms, since they were not reproduced by the histamine H2 receptor 
antagonist famotidine, administered at an equivalent acid-inhibiting dose. More recently, in 
another experimental model of gastric ulceration, elicited by chronic indomethacin 
administration, it was confirmed that esomeprazole can exert antiapoptotic actions on 
gastric mucosal cells in the setting of ulcer repair (Fornai et al., 2011). In the same study, 
treatment with esomeprazole was also associated with a significant increase in mucosal 
expression of PCNA and Ki-67, both regarded as markers of cell proliferation. The beneficial 
influence of esomeprazole on ulcer repair has been related to mechanisms which are likely 
to be independent from the inhibition of acid secretion and ascribable to antioxidant 
properties (Fornai et al., 2011). This view is in line with previous studies reporting that both 
the antioxidant compound ascorbic acid and omeprazole enhanced the expression of growth 
factors, including TGF-, in the gastric mucosa of rats treated with aspirin (Jainu and 
Mohan, 2008). In addition, these preclinical findings are consistent with the clinical evidence  
provided by Tsuji et al. (1995), who showed that lansoprazole, but not famotidine, induced 
the expression of bFGF in the gastric ulcer margin, and that PPI was more effective than 
famotidine in promoting ulcer healing. Other reports have suggested that several growth 
factors are involved in the ulcer healing effects of PPIs. In this regard, Kinoshita et al. (1998) 
observed that the gastric levels of HGF were enhanced by omeprazole in rats with 
indomethacin-induced gastric damage. Moreover, the expression of EGF was found to be 
increased in the gastric mucosa of mice with indomethacin-induced injury, and further 
enhanced by omeprazole (Banerjee et al., 2008). 
6.1 Effects of PPIs on gastric ulcer healing: clinical evidence 
Several clinical studies have been performed to investigate the efficacy of PPIs in promoting 
the healing of mucosal lesions in patients who unavoidably need to continue NSAID 
therapy. In a multicentre study, a subgroup of 68 gastric ulcer patients, who continued using 
NSAIDs, showed rapid ulcer healing when receiving omeprazole 20 and 40 mg/day, with a 
therapeutic advantage of 31% and 43%, respectively, after 8 weeks as compared with 
ranitidine 300 mg (Walan et al., 1989). Subsequently, in the ASTRONAUT  trial, two doses of 
omeprazole (20 and 40 mg/day) were compared with ranitidine (150 mg twice daily) in 
patients with both gastric and duodenal ulcers. In this study, treatment with omeprazole 
was more effective than the H2-receptor antagonist in terms of ulcer healing (Yeomans et al., 
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1998). The clinical effectiveness of omeprazole has also been documented in comparative 
studies with other protective drugs. For example, a therapeutic gain of 18% in gastric ulcer 
patients and 22% in duodenal ulcer patients taking NSAIDs has been estimated when 
comparing omeprazole with sucralfate (Bianchi Porro et al., 1998). By contrast, the 
OMNIUM study did not display significant differences between omeprazole (20 and 40 
mg/day) and misoprostol (200 g four times daily) in terms of ulcer healing (Hawkey et al., 
1998). Similar results were observed for lansoprazole (15 or 30 mg/day) in comparison with 
ranitidine (150 mg twice daily). Both doses of lansoprazole were significantly more effective 
than ranitidine for promoting the healing of gastric ulcers, in patients taking NSAIDs, after 4 
and 8 weeks of treatment. In particular, after 8 weeks, the healing rate was 74% in patients 
treated with lansoprazole 30 mg, and 50% in patients treated with ranitidine 150 mg twice 
daily (Agrawal et al., 2000; Campbell et al., 2002). In a double-blind, placebo-controlled, 
randomized trial, patients, treated with low-dose aspirin and affected by upper digestive 
symptoms, were assigned to treatment with rabeprazole (20 mg once daily) or placebo for 4 
weeks. At the end of this period, 47% of patients treated with rabeprazole and 43% of 
patients given placebo reported a complete relief of upper gastrointestinal symptoms (Laheij 
et al., 2003). Subsequently, two studies were performed to compare esomeprazole (20 or 40 
mg once daily) with ranitidine (Goldstein et al., 2005; 2007). In the first study, gastric ulcer 
healing occurred in significantly higher proportions of patients treated with either 20 or 40 
mg of esomeprazole, as compared with ranitidine at both 4 and 8 weeks. In particular, at the 
end of the 8-week treatment, the healing rate was 74% in the ranitidine group, 88% with 
esomeprazole 20 mg and 92% with esomeprazole 40 mg (Goldstein et al., 2005). The second 
study, performed by the same Authors, highlighted a significant difference in favor of both 
esomeprazole doses only after 4 weeks. By contrast, after 8 weeks, the healing rates were 
similar for esomeprazole (20 and 40 mg/day) in comparison with ranitidine (Goldstein et 
al., 2007).  
7. Novel therapeutic options for prevention and treatment of gastric ulcer 
Although the control of gastric acid secretion represents a cornerstone for the promotion of 
ulcer healing, an increasing interest is growing up about the characterization of the 
mechanisms supporting the process of ulcer repair, and the possibility that both the speed 
and quality of ulcer healing can be pharmacologically modulated.  
At present, novel pharmacological strategies are being investigated to counteract the 
detrimental actions of traditional NSAIDs on the gastrointestinal tract. The main options 
currently under active evaluation are: (i) dual inhibitors of cyclooxygenase and 5-
lipooxygenase (5-LOX), in order to prevent the mucosal injury resulting from the enhanced 
biosynthesis of leukotrienes, arising from the shift of arachidonic acid metabolism towards 
the leukotriene pathway as a consequence of cyclooxygenase inhibition; (ii) traditional 
NSAIDs associated with phosphatidylcholine, to minimize the destabilizing action of these 
drugs on the extracellular mucosal lining of zwitterionic phospholipids; (iii) NO donating 
NSAIDs, designated as cyclooxygenase inhibitors/NO donors (CINODs) and aimed at 
preventing the injurious actions of NSAIDs through the gastroprotective activity of 
exogenous NO; (iv) NSAIDs releasing H2S, a gaseous mediator actively involved in the 
maintenance of digestive mucosal integrity and blood flow (Blandizzi et al., 2009).  
Some of the above mentioned drugs are under clinical development. In particular, 
licofelone, a dual cyclooxygenase/5-LOX inhibitor, has been shown to spare the human 
gastric mucosa (endoscopic endpoint) when administered for 4–12 weeks to healthy 
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volunteers or patients with osteoarthritis in phase II or phase III trials controlled with 
placebo or naproxen (Bias et al., 2004; Becker et al., 2004). In a 4-day study, performed on 
healthy volunteers, the gastric injuring action of aspirin, assessed through endoscopic 
examination, was significantly reduced in subjects administered with soy 
phosphatidylcholine, although in both treatment groups prostaglandin levels in gastric 
biopsies were significantly reduced (Anand et al., 1999). Recently, Lanza et al. (2008) 
evaluated the digestive safety of ibuprofen chemically combined with phosphatidylcholine 
in osteoarthritic patients, observing a better tolerability of this association in comparison 
with ibuprofen alone.  
CINODs have been developed exploiting the concept that NO, released locally in the gastric 
mucosa, would enhance the mucosal blood flow and reduce leukocyte adherence in the 
gastric microcirculation. Based on this assumption, aspirin and other traditional NSAIDs 
have been coupled to a nitroxybutyl or nitrosothiol group to yield novel anti-inflammatory 
entities which release discrete amounts of NO (Fiorucci et al., 2007). At present, the 
pharmacokinetic profile of these novel pharmacological entities remains unclear and 
deserve further investigations. However, encouraging results about the gastric safety 
profiles of these novel drugs arise from studies performed on healthy volunteers. In this 
regard, an endoscopic study demonstrated that healthy subjects treated for 7 days with 
NCX-4016, an NO-donating aspirin, did not display gastrointestinal toxicity (Fiorucci et al., 
2003). On the same line, a trial performed on 31 healthy volunteers showed that upper 
gastrointestinal endoscopic events following oral administration of AZD 3582, a novel NO 
donating naproxen, for 12 days were significantly reduced in comparison with traditional 
naproxen (Hawkey et al., 2003). Moreover, Wilder-Smith et al. (2006) investigated the effects 
of equimolar doses of AZD3582 and traditional naproxen in healthy volunteers treated for 
12 days, observing that treatment with the CINOD was endowed with a better 
gastroduodenal safety profile in comparison with naproxen. Clearly, further clinical studies 
are needed to establish whether CINODs confer actual advantages over traditional NSAIDs 
in terms of upper digestive safety.  
Recently, an increasing attention has been paid to the beneficial effects of H2S on the gastric 
mucosa. This gaseous compound, previously regarded as a toxic agent, is emerging as an 
endogenous modulator which seems to share almost all the beneficial actions of NO on 
several physiological processes. In particular, it has been demonstrated that H2S is produced 
by the gastric mucosa, and that it contributes to the ability of this tissue to resist against 
damage induced by luminal agents (Fiorucci et al., 2007). Interestingly, several lines of 
evidence have shown that H2S donors can prevent the decrease in gastric blood flow 
induced by NSAIDs, and reduce NSAID-induced leukocyte accumulation and adhesion in 
gastric microvessels, thus providing a rationale for the synthesis of H2S-releasing NSAID 
derivatives as novel anti-inflammatory drugs (Fiorucci et al., 2007). As previously observed 
with CINODs, an H2S-releasing derivative of diclofenac was shown to be better tolerated, in 
terms of gastric damage, than traditional NSAIDs. Moreover, the addition of the H2S-
releasing moiety has been found to increase the anti-inflammatory activity of diclofenac 
(Wallace, 2007; Li et al., 2007). Additional strategies for the prevention of NSAID-induced 
upper digestive damage include the ongoing clinical development of pharmaceutical 
products containing fixed combinations of a NSAID with a gastroprotective drug, such as 
naproxen/omeprazole, naproxen/lansoprazole, naproxen/esomeprazole and 
ibuprofen/famotidine (Blandizzi et al., 2009). 
Several studies have focused their attention toward novel approaches to promote the 
healing of gastric ulcer. It has been widely recognized that the healing process requires 
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angiogenesis in the granulation tissue at the ulcer base, followed by a sustained proliferation 
of epithelial cells in ulcer margins and a subsequent re-arrangement of tissue architecture 
(Wallace, 2005). As discussed in this chapter, this complex process is finely regulated. In 
particular, it has been demonstrated PARs play important roles in the modulation of ulcer 
repair. In particular, preclinical studies have suggested PAR1 as a potential therapeutic 
target for promoting ulcer healing (Ma et al., 2005). 
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